Oncolytic Viruses and Brain Cancer Vaccines: New Frontiers in Glioblastoma Immunotherapy

04 Nov Oncolytic Viruses and Brain Cancer Vaccines: New Frontiers in Glioblastoma Immunotherapy

Posted at 12:53h in Brain Cancer - Brain Tumors, Immunotherapy, Vaccine Studies by Marie Benz MD FAAD

Glioblastoma is one of the most challenging cancers to treat due to its aggressive nature and resistance to standard therapies. In recent years, however, the field of glioblastoma immunotherapy has made significant strides, introducing innovative approaches like oncolytic viruses and brain cancer vaccines. These emerging treatments aim to engage the immune system in the fight against glioblastoma, offering new avenues for improving patient outcomes and extending survival rates.

The Current State of Glioblastoma Treatment

With a median survival rate of only 12-15 months, glioblastoma patients face difficult odds. Traditional treatments often manage to slow tumor growth temporarily, but recurrence is common. This grim reality has motivated researchers to explore innovative therapies that leverage the body’s immune system, including oncolytic viruses and personalized vaccines.

Breakthroughs in Oncolytic Virus Therapy

Oncolytic viruses are specially engineered or naturally occurring viruses designed to infect and kill cancer cells while sparing healthy cells. These viruses attack cancer through a two-pronged approach:

Direct Tumor Lysis: Once the virus enters a cancer cell, it replicates rapidly, eventually causing the cell to burst (lysis) and release viral particles to infect nearby cancer cells.
Immune Activation: The process of cell lysis releases tumor-specific antigens that “teach” the immune system to recognize and attack other cancer cells, turning the immune response against the tumor.

Two of the leading oncolytic viruses in glioblastoma research are G47Δ and PVSRIPO:

G47Δ is a modified herpes simplex virus that has shown promising results in Japan. Recent studies reveal that about 20% of glioblastoma patients receiving G47Δ experienced progression-free survival (PFS) at 24 months, a significant improvement over conventional treatments.
PVSRIPO, a modified poliovirus, targets the CD155 receptor, commonly overexpressed in glioblastoma cells. In clinical trials, PVSRIPO has achieved a median overall survival (OS) of 12.5 months, with a subset of patients experiencing long-term remission.

These therapies are still in the experimental stage and are primarily available through clinical trials in specialized cancer centers.

The Role of Brain Cancer Vaccines

Brain cancer vaccines, including dendritic cell vaccines and neoantigen-based vaccines, work by priming the immune system to target cancer cells. Unlike oncolytic viruses, these vaccines don’t attack cancer cells directly but instead “train” the immune system to recognize and fight them.

One of the most studied vaccines is DCVax®-L, a dendritic cell vaccine that uses a patient’s own tumor antigens to stimulate an immune response:

DCVax®-L Clinical Trials: In a Phase III trial with 331 glioblastoma patients, DCVax®-L demonstrated extended median survival times of up to 23.1 months for newly diagnosed patients. This is a notable improvement over the typical 15-month survival rate associated with standard treatments.

Neoantigen vaccines, which are highly personalized based on each patient’s tumor mutations, have also shown promise, especially in enhancing immune response. These vaccines are crafted to target unique mutations within an individual’s tumor, creating a tailored approach that can improve treatment effectiveness.

Combining Oncolytic Viruses with Cancer Vaccines

Research in brain cancer immunotherapy suggests that combining oncolytic viruses with brain cancer vaccines may amplify their effectiveness.

For instance, oncolytic viruses like G47Δ or PVSRIPO can “prime” the immune system by breaking down cancer cells and releasing antigens. This enhances the vaccine’s ability to train immune cells to recognize and attack cancer. Although still under investigation, early results suggest that this combination may yield better survival outcomes than either therapy alone.

Key Considerations for Patients

These innovative treatments are complex and often costly. Here’s what patients considering these therapies should know:

Cost and Accessibility: Oncolytic virus therapies and personalized vaccines are typically available only through clinical trials, and the costs can range from $50,000 to over $200,000 for a full course. Insurance coverage remains limited, and geographic availability is primarily restricted to specialized centers in North America, Japan, and Europe.
Patient Selection: Because these therapies are still experimental, patient eligibility is selective. Generally, patients with recurrent glioblastoma who meet certain health and genetic criteria are more likely to benefit from these treatments.

Monitoring and Follow-Up

Regular monitoring is essential to track treatment progress and manage side effects. Standard follow-up includes:

- MRI Scans every 2-3 months to assess tumor response.
- Immune Marker Testing to evaluate immune activation and potential side effects, such as inflammation or autoimmune reactions.

The Future of Glioblastoma Immunotherapy

The integration of oncolytic viruses and cancer vaccines is still in its early stages, but ongoing research is paving the way for more targeted and effective glioblastoma treatments. While significant challenges remain, these therapies offer a glimmer of hope, showing that the immune system can be harnessed in the battle against one of the deadliest cancers.

Tags:

#cancervaccines, #oncolyticviruses, @braincancer, glioblastoma